Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
L-glutamine has been approved in the US to reduce the acute complications of sickle cell
disease (SCD) in adult and pediatric patients 5 years of age and older. The purpose of this
single-center, open-label, phase 4 study is to evaluate the pharmacokinetic characteristics
and safety of L-glutamine in patients with SCD.